Daniel P. Silver, MD, PhD

Director, Basic Science & Research, Medical Oncology
Leader, Molecular Oncology Regulation & Approaches Program - Sidney Kimmel Comprehensive Cancer Center
Professor

Contact Information

Daniel Silver, MD

Honickman Center
1101 Chestnut Street
14th Floor
Philadelphia, PA 19107

Email Dr. Silver

215-955-8874

Director, Basic Science & Research, Medical Oncology
Leader, Molecular Oncology Regulation & Approaches Program - Sidney Kimmel Comprehensive Cancer Center
Professor

REASERCH & CLINICAL INTERESTS

Dr. Silver's research focuses on understanding the molecular mechanisms underlying breast cancer, particularly triple-negative breast cancer (TNBC), and developing targeted therapies. His laboratory has identified MECP2 as a novel oncogene amplified in various cancers, including TNBC, and has explored its potential as a therapeutic target. He has also contributed to the development of the Homologous Recombination Deficiency (HRD) assay, a biomarker test that predicts chemotherapy responsiveness in TNBC by identifying DNA repair defects .

His work has led to clinical trials investigating the efficacy of platinum-based therapies and PARP inhibitors in patients with BRCA1/2 mutations and HRD-positive tumors .

Education

Medical School

University of California, San Francisco, CA - 1994

Residency

University of California, San Francisco, CA

Fellowship

Dana-Farber/Harvard Oncology, Boston, MA

Graduate

Massachusetts Institute of Technology, Boston, MA

Most Recent Peer-Reviewed Publications

Board Certification

Medical Oncology Board Certified


Featured Links